Breakthrough T1D Awards Grant to MannKind for Afrezza Pediatric Trial Advancement
MNKD sits 72% above its 52-week low of $2.23.
Summary
MannKind has been awarded a grant from Breakthrough T1D (formerly JDRF) to support its INHALE-1ST clinical study, which is evaluating Afrezza in youth newly diagnosed with Type 1 Diabetes. This grant provides external validation and non-dilutive funding for a key pediatric trial. It builds on the recent FDA approval of Afrezza for pediatric use, underscoring the potential for the inhaled insulin in a significant new market segment. This support helps de-risk the trial and highlights Afrezza's role in addressing unmet needs in pediatric diabetes care.
At the time of this announcement, MNKD was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.